These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
328 related articles for article (PubMed ID: 15572393)
1. Intravenous immunoglobulin does not increase FcgammaRIIB expression on monocytes/macrophages during acute Kawasaki disease. Ichiyama T; Ueno Y; Hasegawa M; Ishikawa Y; Matsubara T; Furukawa S Rheumatology (Oxford); 2005 Mar; 44(3):314-7. PubMed ID: 15572393 [TBL] [Abstract][Full Text] [Related]
2. NF-kappaB activation in peripheral blood monocytes/macrophages and T cells during acute Kawasaki disease. Ichiyama T; Yoshitomi T; Nishikawa M; Fujiwara M; Matsubara T; Hayashi T; Furukawa S Clin Immunol; 2001 Jun; 99(3):373-7. PubMed ID: 11358434 [TBL] [Abstract][Full Text] [Related]
3. Intravenous immunoglobulin does not increase FcγRIIB expression levels on monocytes in children with immune thrombocytopenia. Shimomura M; Hasegawa S; Seki Y; Fukano R; Hotta N; Ichiyama T Clin Exp Immunol; 2012 Jul; 169(1):33-7. PubMed ID: 22670776 [TBL] [Abstract][Full Text] [Related]
4. Intravenous immunoglobulin inhibits NF-kappaB activation and affects Fcgamma receptor expression in monocytes/macrophages. Ichiyama T; Ueno Y; Hasegawa M; Niimi A; Matsubara T; Furukawa S Naunyn Schmiedebergs Arch Pharmacol; 2004 Apr; 369(4):428-33. PubMed ID: 14985941 [TBL] [Abstract][Full Text] [Related]
5. Preparations of intravenous immunoglobulins diminish the number and proinflammatory response of CD14+CD16++ monocytes in common variable immunodeficiency (CVID) patients. Siedlar M; Strach M; Bukowska-Strakova K; Lenart M; Szaflarska A; Węglarczyk K; Rutkowska M; Baj-Krzyworzeka M; Pituch-Noworolska A; Kowalczyk D; Grodzicki T; Ziegler-Heitbrock L; Zembala M Clin Immunol; 2011 May; 139(2):122-32. PubMed ID: 21300572 [TBL] [Abstract][Full Text] [Related]
6. Expression of FcRs on monocytes among Kawasaki disease patients with coronary artery lesions. Xia Y; Tian X; Li Q; Wang G; Li C; Yang J Int Immunopharmacol; 2017 Apr; 45():1-5. PubMed ID: 28147297 [TBL] [Abstract][Full Text] [Related]
7. Persistent monocytosis after intravenous immunoglobulin therapy correlated with the development of coronary artery lesions in patients with Kawasaki disease. Kuo HC; Wang CL; Liang CD; Yu HR; Chen HH; Wang L; Yang KD J Microbiol Immunol Infect; 2007 Oct; 40(5):395-400. PubMed ID: 17932598 [TBL] [Abstract][Full Text] [Related]
8. Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited. Hsieh KS; Weng KP; Lin CC; Huang TC; Lee CL; Huang SM Pediatrics; 2004 Dec; 114(6):e689-93. PubMed ID: 15545617 [TBL] [Abstract][Full Text] [Related]
10. The B cell superantigen-like interaction of intravenous immunoglobin (IVIG) with Fab fragments of V(H) 3-23 and 3-30/3-30.5 germline gene origin cloned from a patient with Kawasaki disease is enhanced after IVIG therapy. Leucht S; Uttenreuther-Fischer MM; Gaedicke G; Fischer P Clin Immunol; 2001 Apr; 99(1):18-29. PubMed ID: 11286538 [TBL] [Abstract][Full Text] [Related]
11. Adsorptive depletion of elevated proinflammatory CD14+CD16+DR++ monocytes in patients with inflammatory bowel disease. Hanai H; Iida T; Takeuchi K; Watanabe F; Yamada M; Kikuyama M; Maruyama Y; Iwaoka Y; Hirayama K; Nagata S; Takai K Am J Gastroenterol; 2008 May; 103(5):1210-6. PubMed ID: 18177452 [TBL] [Abstract][Full Text] [Related]
12. A shift in the balance of inhibitory and activating Fcgamma receptors on monocytes toward the inhibitory Fcgamma receptor IIb is associated with prevention of monocyte activation in rheumatoid arthritis. Wijngaarden S; van de Winkel JG; Jacobs KM; Bijlsma JW; Lafeber FP; van Roon JA Arthritis Rheum; 2004 Dec; 50(12):3878-87. PubMed ID: 15593228 [TBL] [Abstract][Full Text] [Related]
14. High-dose intravenous immunoglobulin downregulates the activated levels of inflammatory indices except erythrocyte sedimentation rate in acute stage of Kawasaki Disease. Lee KY; Lee HS; Hong JH; Han JW; Lee JS; Whang KT J Trop Pediatr; 2005 Apr; 51(2):98-101. PubMed ID: 15677370 [TBL] [Abstract][Full Text] [Related]
15. Early activation does not translate into effector differentiation of peripheral CD8T cells during the acute phase of Kawasaki disease. Ehara H; Kiyohara K; Izumisawa Y; Ito T Cell Immunol; 2010; 265(1):57-64. PubMed ID: 20673885 [TBL] [Abstract][Full Text] [Related]
16. Effects of steroid pulse therapy on immunoglobulin-resistant Kawasaki disease. Furukawa T; Kishiro M; Akimoto K; Nagata S; Shimizu T; Yamashiro Y Arch Dis Child; 2008 Feb; 93(2):142-6. PubMed ID: 17962370 [TBL] [Abstract][Full Text] [Related]
17. The "Intermediate" CD14 + CD16 + monocyte subpopulation plays a role in IVIG responsiveness of children with Kawasaki disease. Kim YS; Yang HJ; Kee SJ; Choi I; Ha K; Ki KK; Jeong IS; Cho HJ Pediatr Rheumatol Online J; 2021 May; 19(1):76. PubMed ID: 34059085 [TBL] [Abstract][Full Text] [Related]
18. Decreased expression of CD23 on peripheral blood macrophages/monocytes during acute Kawasaki disease with coronary artery lesions. Furukawa S; Matsubara T; Okumura K; Yabuta K Int Arch Allergy Immunol; 1993; 102(4):335-9. PubMed ID: 7694701 [TBL] [Abstract][Full Text] [Related]
19. The effect of FcγRIIA and FcγRIIB on coronary artery lesion formation and intravenous immunoglobulin treatment responses in children with Kawasaki disease. Chang LS; Lo MH; Li SC; Yang MY; Hsieh KS; Kuo HC Oncotarget; 2017 Jan; 8(2):2044-2052. PubMed ID: 27893416 [TBL] [Abstract][Full Text] [Related]
20. Can antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? Siragam V; Brinc D; Crow AR; Song S; Freedman J; Lazarus AH J Clin Invest; 2005 Jan; 115(1):155-60. PubMed ID: 15630455 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]